Platelet-rich Plasma Market Size, Share, Growth, Trends, Consumption, Revenue, Company Analysis, Regional Insights and Forecast 2021-2028

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Platelet Rich Plasma Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Platelet Rich Plasma Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Pricing Analysis

    5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Platelet Rich Plasma Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017–2031

        6.3.1. Pure-PRP

        6.3.2. Leukocyte-rich PRP

        6.3.3. Pure-PRF

    6.4. Market Attractiveness Analysis, by Type

7. Global Platelet Rich Plasma Market Analysis and Forecast, by Origin

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Origin, 2017–2031

        7.3.1. Autologous

        7.3.2. Allogeneic

        7.3.3. Homologous

    7.4. Market Attractiveness Analysis, by Origin

8. Global Platelet Rich Plasma Market Analysis and Forecast, by Application

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Application, 2017–2031

        8.3.1. Orthopedic Surgery

        8.3.2. Cosmetic Surgery

        8.3.3. General Surgery

        8.3.4. Neurosurgery

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by Application

9. Global Platelet Rich Plasma Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast By Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Country/Region

10. North America Global Platelet Rich Plasma Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017–2031

        10.2.1. Pure-PRP

        10.2.2. Leukocyte-rich PRP

        10.2.3. Pure-PRF

    10.3. Market Value Forecast, by Origin, 2017–2031

        10.3.1. Autologous

        10.3.2. Allogeneic

        10.3.3. Homologous

    10.4. Market Value Forecast, by Application, 2017–2031

        10.4.1. Orthopedic Surgery

        10.4.2. Cosmetic Surgery

        10.4.3. General Surgery

        10.4.4. Neurosurgery

        10.4.5. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Origin

        10.6.3. By Application

        10.6.4. By Country

11. Europe Global Platelet Rich Plasma Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017–2031

        11.2.1. Pure-PRP

        11.2.2. Leukocyte-rich PRP

        11.2.3. Pure-PRF

    11.3. Market Value Forecast, by Origin, 2017–2031

        11.3.1. Autologous

        11.3.2. Allogeneic

        11.3.3. Homologous

    11.4. Market Value Forecast, by Application, 2017–2031

        11.4.1. Orthopedic Surgery

        11.4.2. Cosmetic Surgery

        11.4.3. General Surgery

        11.4.4. Neurosurgery

        11.4.5. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Origin

        11.6.3. By Application

        11.6.4. By Country/Sub-region

12. Asia Pacific Global Platelet Rich Plasma Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017–2031

        12.2.1. Pure-PRP

        12.2.2. Leukocyte-rich PRP

        12.2.3. Pure-PRF

    12.3. Market Value Forecast, by Origin, 2017–2031

        12.3.1. Autologous

        12.3.2. Allogeneic

        12.3.3. Homologous

    12.4. Market Value Forecast By Application, 2017–2031

        12.4.1. Orthopedic Surgery

        12.4.2. Cosmetic Surgery

        12.4.3. General Surgery

        12.4.4. Neurosurgery

        12.4.5. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Origin

        12.6.3. By Application

        12.6.4. By Country/Sub-region

13. Latin America Global Platelet Rich Plasma Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017–2031

        13.2.1. Pure-PRP

        13.2.2. Leukocyte-rich PRP

        13.2.3. Pure-PRF

    13.3. Market Value Forecast, by Origin, 2017–2031

        13.3.1. Autologous

        13.3.2. Allogeneic

        13.3.3. Homologous

    13.4. Market Value Forecast, by Application, 2017–2031

        13.4.1. Orthopedic Surgery

        13.4.2. Cosmetic Surgery

        13.4.3. General Surgery

        13.4.4. Neurosurgery

        13.4.5. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Origin

        13.6.3. By Application

        13.6.4. By Country/Sub-region

14. Middle East & Africa Global Platelet Rich Plasma Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017–2031

        14.2.1. Pure-PRP

        14.2.2. Leukocyte-rich PRP

        14.2.3. Pure-PRF

    14.3. Market Value Forecast, by Origin, 2017–2031

        14.3.1. Autologous

        14.3.2. Allogeneic

        14.3.3. Homologous

    14.4. Market Value Forecast, by Application, 2017–2031

        14.4.1. Orthopedic Surgery

        14.4.2. Cosmetic Surgery

        14.4.3. General Surgery

        14.4.4. Neurosurgery

        14.4.5. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Origin

        14.6.3. By Application

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Company Profiles

        15.2.1. Zimmer Biomet Holdings, Inc.

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview

            15.2.1.3. Product Portfolio

            15.2.1.4. Strategic Overview

            15.2.1.5. SWOT Analysis

        15.2.2. AdiStem Ltd.

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Financial Overview

            15.2.2.3. Product Portfolio

            15.2.2.4. Strategic Overview

            15.2.2.5. SWOT Analysis

        15.2.3. ISTO Biologics

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview

            15.2.3.3. Product Portfolio

            15.2.3.4. Strategic Overview

            15.2.3.5. SWOT Analysis

        15.2.4. ThermoGenesis Holdings, Inc.

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Financial Overview

            15.2.4.3. Product Portfolio

            15.2.4.4. Strategic Overview

            15.2.4.5. SWOT Analysis

        15.2.5. Stryker Corporation

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview

            15.2.5.3. Product Portfolio

            15.2.5.4. Strategic Overview

            15.2.5.5. SWOT Analysis

        15.2.6. Exactech, Inc.

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview

            15.2.6.3. Product Portfolio

            15.2.6.4. Strategic Overview

            15.2.6.5. SWOT Analysis

        15.2.7. EmCyte Corporation

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview

            15.2.7.3. Product Portfolio

            15.2.7.4. Strategic Overview

            15.2.7.5. SWOT Analysis

        15.2.8. Regen Lab

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Financial Overview

            15.2.8.3. Product Portfolio

            15.2.8.4. Strategic Overview

            15.2.8.5. SWOT Analysis

        15.2.9. Arthrex, Inc.

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Financial Overview

            15.2.9.3. Product Portfolio

            15.2.9.4. Strategic Overview

            15.2.9.5. SWOT Analysis

        15.2.10. TERUMO BCT, INC. (Terumo Corporation)

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Financial Overview

            15.2.10.3. Product Portfolio

            15.2.10.4. Strategic Overview

            15.2.10.5. SWOT Analysis

        15.2.11. DePuy Synthes Companies (Johnson & Johnson)

            15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.11.2. Financial Overview

            15.2.11.3. Product Portfolio

            15.2.11.4. Strategic Overview

            15.2.11.5. SWOT Analysis

        15.2.12. APEX Biologix, LLC

            15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.12.2. Financial Overview

            15.2.12.3. Product Portfolio

            15.2.12.4. Strategic Overview

            15.2.12.5. SWOT Analysis

Report Details

  • Report Code:36635
  • Category:Healthcare
  • No. of Pages:200
  • Format:PDF/PPT/Excel
  • Published:September 2022
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers